Artystarty Baird started coverage of TransMedics Group ( NASDAQ: TMDX ) with an outperform rating, commenting that the company’s organ care technology has driven a “paradigm shift and accelerated growth” in the organ transplant market. “With TMDX still in the early innings of capturing.
Back to Health Page
